Developing high-quality medicine is a resource-intense endeavor that requires collaboration across Novo Nordisk. Novo Nordisk aimed to scale a pipeline of drug discovery, development, and data science capabilities with AI and machine learning. In partnership with Microsoft Research, the teams built a Novo Nordisk AI platform on Azure AI and data stacks. Novo Nordisk amplified its culture of innovation by leveraging Microsoft Azure platform's AI capabilities across many use cases. The teams recently published initial results with predictive AI models for advanced risk detection in cardiovascular diseases, including an algorithm that can predict patients' cardiovascular risk better than the best clinical standards. Read this case study for lessons learned.
How is Novo Nordisk using AI in drug discovery?
Novo Nordisk is leveraging AI and machine learning to enhance its drug discovery and development processes. By building a dedicated AI platform on Microsoft Azure, the company is able to scale its capabilities and improve collaboration among life scientists, computational biologists, and data scientists. This approach has led to the development of predictive AI models that can detect cardiovascular disease risks more effectively than traditional clinical standards.
What are the benefits of the partnership with Microsoft Research?
The partnership with Microsoft Research allows Novo Nordisk to combine its extensive domain expertise in life sciences with Microsoft's advanced AI capabilities. This collaboration has resulted in the creation of a comprehensive AI platform that supports various use cases, including regulatory affairs and trial design, enabling more efficient and innovative approaches to drug discovery.
What impact does AI have on patient care?
AI is reshaping patient care at Novo Nordisk by enabling the definition of patients' risks for developing diseases, which is essential for precision medicine. With over 100 years of data on insulin research, the integration of AI allows Novo Nordisk to provide better treatment options for conditions related to diabetes, such as obesity and cardiovascular diseases, ultimately improving patient outcomes.
.jpg "FANTINI FABRIZIO"){kind=logo}
Sign in with LinkedIn